First Tracks (TRAX) Director John A. Orwin Converts 1,300 RSUs

What Happened
John A. Orwin, a director of First Tracks Biotherapeutics (TRAX), had 1,300 restricted stock units (RSUs) settled into 1,300 shares on September 15, 2026. The filing shows an acquisition of 1,300 shares at $0.00 (settlement of RSUs) and a corresponding conversion/disposition reporting line for 1,300 derivative units at $0.00. No cash was paid for these shares—this was a vesting/settlement of awards, not a market purchase or sale for proceeds.

Key Details

• Transaction date: 2026-09-15; reported on Form 4 filed 2026-09-17 (filed within the typical 2-business-day Form 4 window).
• Reported amounts/prices: Acquired 1,300 shares @ $0.00; corresponding derivative conversion/disposition of 1,300 @ $0.00. Total cash value reported: $0.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 — each RSU converts to 1 common share upon settlement for no consideration; F2 — the RSUs vest 1/3 on 9/15/2024, 1/3 on 9/15/2025, and 1/3 on 9/15/2026, subject to continued service. The 1,300-share settlement likely represents the final 1/3 of a 3,900-RSU award.
• Transaction code: M (exercise or conversion of a derivative/security); no 10b5-1 plan or tax-withholding sale was disclosed.

Context
This was an RSU settlement (award conversion) rather than an open-market purchase or sale. Such settlements increase an insider’s reported share count without reflecting a cash outlay or market-driven buying/selling activity; they are generally routine when awards vest. Because the filing does not show an immediate sale of the underlying shares for proceeds, there is no direct evidence here of a market disposition.